The prognostic impact of TGF-β1, fascin, NF-κb and PKC-ζ expression in soft tissue sarcomas

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Valkov, Andrej ^a,b   Sorbye, Sveinung W ^a,b   Kilvaer, Thomas K ^b   Donnem, Tom ^a,b   Smeland, Eivind ^a   Bremnes, Roy M ^a,b   Busund, Lill Tove ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FASCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR FACTOR KAPPA B P105; PARTITIONING DEFECTIVE PROTEIN 6 ALPHA; PROTEIN KINASE C ZETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ACTIN BINDING PROTEIN; CARRIER PROTEIN; PROTEIN KINASE C;

ADULT; AGED; AGGRESSION; ARTICLE; CELL DEDIFFERENTIATION; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SOFT TISSUE SARCOMA; TISSUE MICROARRAY; TUMOR CELL; ADOLESCENT; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NORWAY; OBSERVER VARIATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SARCOMA; SURVIVAL;

ADOLESCENT; ADULT; CARRIER PROTEINS; CELL DEDIFFERENTIATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NF-KAPPA B; NORWAY; OBSERVER VARIATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE C; SARCOMA; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79952307049     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017507     Document Type: Article

References (48)

1. Gustafson P, (1994) Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand 259 (Suppl): 1-31.
2. Wibmer C, Leithner A, Zielonke N, Sperl M, Windhager R, (2010) Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review. Ann Oncol 21: 1106-1111.
3. Engellau J, Anderson H, Rydholm A, Bauer HC, Hall KS, et al. (2004) Time dependence of prognostic factors for patients with soft tissue sarcoma: a Scandinavian Sarcoma Group Study of 338 malignant fibrous histiocytomas. Cancer 100: 2233-2239.
4. Dickinson IC, Whitwell DJ, Battistuta D, Thompson B, Strobel N, et al. (2006) Surgical margin and its influence on survival in soft tissue sarcoma. ANZ J Surg 76: 104-109.
5. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, et al. (2003) Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 57: 739-747.
6. Raney RB Jr, Crist WM, Maurer HM, Foulkes MA, (1983) Prognosis of children with soft tissue sarcoma who relapse after achieving a complete response. A report from the Intergroup Rhabdomyosarcoma Study I. Cancer 52: 44-50.
7. Kiatisevi P, Asavamongkolkul A, Phimolsarnti R, Waikakul S, Benjarassamerote S, (2006) The outcomes and prognostic factors of patients with soft-tissue sarcoma. J Med Assoc Thai 89: 334-342.
8. Yang RS, Lane JM, Eilber FR, Dorey FJ, al Shaikh R, et al. (1995) High grade soft tissue sarcoma of the flexor fossae. Size rather than compartmental status determine prognosis. Cancer 76: 1398-1405.
9. Mendenhall WM, Zlotecki RA, Hochwald SN, Hemming AW, Grobmyer SR, et al. (2005) Retroperitoneal soft tissue sarcoma. Cancer 104: 669-675.
10. Koea JB, Leung D, Lewis JJ, Brennan MF, (2003) Histopathologic type: an independent prognostic factor in primary soft tissue sarcoma of the extremity? Ann Surg Oncol 10: 432-440.
11. Guillou L, Aurias A, (2009) Soft tissue sarcomas with complex genomic profiles. Virchows Arch.
12. Verweij J, Baker LH, (2010) Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. Eur J Cancer 46: 863-868.
13. Beck AH, West RB, van de RM, (2010) Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers. Virchows Arch 456: 141-151.
14. Hugo H, Ackland ML, Blick T, Lawrence MG, et al. (2007) Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213: 374-383.
15. Zeisberg M, Neilson EG, (2009) Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119: 1429-1437.
16. De Wever O, Pauwels P, De Craene B, Sabbah M, Emami S, et al. (2008) Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol 130: 481-494.
17. Campbell KJ, O'Shea JM, Perkins ND, (2006) Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors. BMC Cancer 6: 101.
18. Guo H, Zhang HY, Wang SL, Ye L, Yang GH, et al. (2007) Smad4 and ERK2 stimulated by transforming growth factor beta1 in rhabdomyosarcoma. Chin Med J (Engl) 120: 515-521.
19. Javelaud D, Poupon MF, Wietzerbin J, Besancon F, (2002) Inhibition of constitutive NF-kappa B activity suppresses tumorigenicity of Ewing sarcoma EW7 cells. Int J Cancer 98: 193-198.
20. Liu J, Zhan M, Hannay JA, Das P, Bolshakov SV, et al. (2006) Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. Mol Cancer Res 4: 803-810.
21. Yamamoto T, Akisue T, Marui T, Fujita I, Matsumoto K, et al. (2004) Expression of transforming growth factor beta isoforms and their receptors in malignant fibrous histiocytoma of soft tissues. Clin Cancer Res 10: 5804-5807.
22. Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone Lyon IARC press.
23. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, et al. (2002) High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 20: 2417-2428.
24. Tarin D, Thompson EW, Newgreen DF, (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65: 5996-6000.
25. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, et al. (2009) A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol 11: 943-950.
26. Massague J, (2008) TGFbeta in Cancer. Cell 134: 215-230.
27. Yang L, Pang Y, Moses HL, (2010) TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31: 220-227.
28. Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Baron AE, et al. (2009) The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest 119: 2678-2690.
29. Chen MF, Lee KD, Lu MS, Chen CC, Hsieh MJ, et al. (2009) The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma. J Mol Med 87: 307-320.
30. Masi L, Malentacchi C, Campanacci D, Franchi A, (2002) Transforming growth factor-beta isoform and receptor expression in chondrosarcoma of bone. Virchows Arch 440: 491-497.
31. Kloen P, Gebhardt MC, Perez-Atayde A, Rosenberg AE, Springfield DS, et al. (1997) Expression of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas: TGF-beta3 is related to disease progression. Cancer 80: 2230-2239.
32. Bierie B, Moses HL, (2006) Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6: 506-520.
33. Ikushima H, Miyazono K, (2010) TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 10: 415-424.
34. Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, et al. (2011) Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One 6: e14611.
35. Kilvaer TK, Valkov A, Sorbye S, Smeland E, Bremnes RM, et al. (2010) Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis. PLoS One 5: e15368.
36. Zou J, Yang H, Chen F, Zhao H, Lin P, et al. (2010) Prognostic significance of fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma. Eur J Cancer Prev 19: 11-17.
37. Blaukovitsch M, Halbwedl I, Kothmaier H, Gogg-Kammerer M, Popper HH, (2006) Sarcomatoid carcinomas of the lung-are these histogenetically heterogeneous tumors? Virchows Arch 449: 455-461.
38. Kefeli M, Yildiz L, Kaya FC, Aydin O, Kandemir B, (2009) Fascin expression in uterine smooth muscle tumors. Int J Gynecol Pathol 28: 328-333.
39. Sethi G, Sung B, Aggarwal BB, (2008) Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) 233: 21-31.
40. Al Saad S, Al Shibli K, Donnem T, Persson M, Bremnes RM, et al. (2008) The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer 99: 1476-1483.
41. Liu XF, Ishida H, Raziuddin R, Miki T, (2004) Nucleotide exchange factor ECT2 interacts with the polarity protein complex Par6/Par3/protein kinase Czeta (PKCzeta) and regulates PKCzeta activity. Mol Cell Biol 24: 6665-6675.
42. Thiery JP, Huang R, (2005) Linking epithelial-mesenchymal transition to the well-known polarity protein Par6. Dev Cell 8: 456-458.
43. Guizzetti M, Costa LG, (2000) Possible role of protein kinase C zeta in muscarinic receptor-induced proliferation of astrocytoma cells. Biochem Pharmacol 60: 1457-1466.
44. Guo H, Gu F, Li W, Zhang B, Niu R, et al. (2009) Reduction of protein kinase C zeta inhibits migration and invasion of human glioblastoma cells. J Neurochem 109: 203-213.
45. Cornford P, Evans J, Dodson A, Parsons K, Woolfenden A, et al. (1999) Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol 154: 137-144.
46. Vora HH, Patel NA, Rajvik KN, Mehta SV, Brahmbhatt BV, et al. (2009) Cytokeratin and vimentin expression in breast cancer. Int J Biol Markers 24: 38-46.
47. Kim MA, Lee HS, Lee HE, Kim JH, Yang HK, et al. (2009) Prognostic importance of epithelial-mesenchymal transition-related protein expression in gastric carcinoma. Histopathology 54: 442-451.
48. Liu LK, Jiang XY, Zhou XX, Wang DM, Song XL, et al. (2009) Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol.